Comparative Pharmacology
Head-to-head clinical analysis: NUCYNTA ER versus OPANA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NUCYNTA ER versus OPANA.
NUCYNTA ER vs OPANA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Tapentadol is a mu-opioid receptor agonist and norepinephrine reuptake inhibitor, providing analgesic effects through opioid receptor activation and modulation of descending pain pathways.
Mu-opioid receptor agonist; produces analgesia by binding to opioid receptors in the CNS, inhibiting ascending pain pathways and altering pain perception.
100 mg orally every 12 hours, titrated from 50 mg every 12 hours; maximum 200 mg every 12 hours.
5-20 mg orally every 4-6 hours as needed for pain; extended-release tablets: 5 mg orally every 12 hours, titrated up to 20 mg every 12 hours.
None Documented
None Documented
Terminal elimination half-life: 4.1 hours (range 3.3–4.7 h) after single oral dose; steady state: 4.4 h. No clinically relevant accumulation.
Terminal elimination half-life is 11-16 hours (mean 14 hours) in adults; prolonged in hepatic impairment (up to 30 hours) and elderly.
Renal: 99% (tapentadol and glucuronide conjugates); Fecal: <1%; unchanged tapentadol: <5%.
Primarily renal (approximately 90% as conjugated metabolites, 10% unchanged); biliary/fecal elimination accounts for <10%.
Category C
Category C
Opioid Analgesic
Opioid Analgesic